Last €63.15 EUR
Change Today +0.60 / 0.96%
Volume 300.0
ZEGA On Other Exchanges
New York
As of 9:42 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc-spons adr (ZEGA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/26/15 - €64.20
52 Week Low
02/7/14 - €44.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

astrazeneca plc-spons adr (ZEGA) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc-spons adr (ZEGA) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc-spons adr (ZEGA) Key Developments

BioInvent International AB Appoints Anna Wickenberg as Vice President Clinical Development

BioInvent International AB announced that Anna Wickenberg has been appointed as Vice President Clinical Development, responsible for the clinical development of BioInvent's drug development projects. She will be part of the Management group and reports to the CEO. Most recently, Anna was responsible for the clinical development of new chemical entities in an orphan indication within CNS at Teva.

Heptares Technology Enables Breakthrough in Drug Discovery Collaboration with AstraZeneca

Heptares Therapeutics announced significant progress in its drug discovery collaboration with AstraZeneca. Using Heptares proprietary StaR technology, the first-ever stable version of Protease-Activated Receptor-2 (PAR2) in a therapeutically relevant form has been generated, from which its X-ray structure has been solved. PAR2 is a G protein-coupled receptor (GPCR) that is a well-validated target for multiple indications in pain and inflammatory diseases. Working with scientists at AstraZeneca, the PAR2 StaR protein was used to screen compound libraries resulting in the identification of a hit series of small molecules that bind and block its activity. The X-ray structure information, which yields new details about the unusual binding pocket of PAR2, is now being used at AstraZeneca to further optimize the hit molecules; to increase their binding affinity, potency as antagonists as well as improving their drug-like properties (e.g. oral bioavailability and stability).

Astrazeneca Announces European Medicines Agency Accepted Marketing Authorisation Application for Lesinurad 200Mg Tablets

AstraZeneca announced the European Medicines Agency has accepted the Marketing Authorisation Application (MAA) for lesinurad 200mg tablets. Lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted. The MAA filing was based on data from the CLEAR1, CLEAR2 and CRYSTAL pivotal Phase III combination therapy studies. CLEAR1 and CLEAR2 were 12-month, multicentre, randomised, placebo-controlled studies that evaluated the efficacy and safety of a once daily dose of lesinurad in combination with allopurinol versus allopurinol alone, in symptomatic gout patients not achieving target serum uric acid (sUA) levels on their current allopurinol therapy. CRYSTAL was a 12-month, multicentre, randomised, placebo-controlled study that evaluated the efficacy and safety of a once daily dose of lesinurad in combination with febuxostat compared to febuxostat alone in gout patients with tophi (deposits of uric acid crystals in joints and skin).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEGA:GR €63.15 EUR +0.60

ZEGA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.30 USD +1.45
Biogen Idec Inc $353.56 USD +2.38
Bristol-Myers Squibb Co $61.20 USD -0.13
Celgene Corp $120.72 USD +1.75
Novo Nordisk A/S kr299.90 DKK +1.50
View Industry Companies

Industry Analysis


Industry Average

Valuation ZEGA Industry Range
Price/Earnings 88.0x
Price/Sales 3.5x
Price/Book 4.4x
Price/Cash Flow 88.0x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at